Serum peptidome profiling revealed platelet factor 4 as a potential discriminating peptide associated with pancreatic cancer

Clinical Cancer Research

Volumn 15, Issue 11, 2009, Pages 3812-3819

  Fiedler, Georg Martin ^a   Leichtle, Alexander Benedikt ^a   Kase, Julia ^a   Baumann, Sven ^a   Ceglarek, Uta ^a   Felix, Klaus ^c   Conrad, Tim ^b   Witzigmann, Helmut ^a   Weimann, Arved ^d   Schütte, Christof ^b   Hauss, Johann ^a   Büchler, Markus ^c   Thiery, Joachim ^a  

^a UNIVERSITY HOSPITAL LEIPZIG   (Germany)

^b FREIE UNIVERSITÄT BERLIN   (Germany)

^c UNIVERSITY OF HEIDELBERG   (Germany)

^d Klinikum St Georg   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CA 19-9 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; THROMBOCYTE FACTOR 4; TUMOR MARKER;

ADULT; AGED; ANALYTIC METHOD; AREA UNDER THE CURVE; ARTICLE; BIOINFORMATICS; BLOOD ANALYSIS; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; IMMUNOAFFINITY CHROMATOGRAPHY; MALE; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; PANCREAS CANCER; PRIORITY JOURNAL; PROTEIN ANALYSIS; SENSITIVITY AND SPECIFICITY;

BLOOD PROTEINS; CA-19-9 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; DIAGNOSIS, DIFFERENTIAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; PANCREATIC NEOPLASMS; PLATELET FACTOR 4; PROTEOMICS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; TUMOR MARKERS, BIOLOGICAL;

EID: 66649092902     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-08-2701     Document Type: Article

References (47)

1. Lowenfels AB, Maisonneuve P. Epidemiology and risk factors for pancreatic cancer. Best Pract Res Clin Gastroenterol 2006;20:197-209.
2. Michl P, Pauls S, Gress TM. Evidence-based diagnosis and staging of pancreatic cancer. Best Pract Res Clin Gastroenterol 2006;20:227-251
3. Chen R, Yi EC, Donohoe S, et al. Pancreatic cancer proteome: the proteins that underlie invasion, metastasis, and immunologic escape. Gastroenterology 2005;129:1187-1197 (Pubitemid 41446859)
4. Misek DE, Patwa TH, Lubman DM, Simeone DM. Early detection and biomarkers in pancreatic cancer. J Natl Compr Canc Netw 2007;5:1034-1041 (Pubitemid 350247711)
5. Hess V, Glimelius B, Grawe P, et al. CA 19-9 tumour- marker response to chemotherapy in patients with advanced pancreatic cancer enrolled in a randomised controlled trial. Lancet Oncol 2008;9:132-138
6. Aebersold R, Mann M. Mass spectrometrybased proteomics. Nature 2003;422:198-207.
7. Liotta LA, Ferrari M, Petricoin E. Clinical proteomics: written in blood. Nature 2003;425:905.
8. Rai AJ, Chan DW. Cancer proteomics: serum diagnostics for tumor marker discovery. Ann N Y Acad Sci 2004;1022:286-294 (Pubitemid 38951616)
9. Coombes KR, Morris JS, Hu J, Edmonson SR, Baggerly KA. Serum proteomics profiling - a young technology begins to mature. Nat Biotechnol 2005;23:291-292 (Pubitemid 41094414)
10. Diamandis EP, van der Merwe DE. Plasma protein profiling by mass spectrometry for cancer diagnosis: opportunities and limitations. Clin Cancer Res 2005;11:963-965
11. Hortin GL, Jortani SA, Ritchie JC, Jr., Valdes R, Jr., Chan DW. Proteomics: a new diagnostic frontier. Clin Chem 2006;52:1218-1222
12. Beretta L. Proteomics from the clinical perspective: many hopes and much debate. Nat Methods 2007;4:785-786 (Pubitemid 350055574)
13. Grantzdorffer I, Carl-McGrath S, Ebert MP, Rocken C. Proteomics of pancreatic cancer. Pancreas 2008;36:329-336
14. Check E. Proteomics and cancer: running before we can walk? Nature 2004;429:496-497
15. Diamandis EP. Analysis of serum proteomic patterns for early cancer diagnosis: drawing attention to potential problems. J Natl Cancer Inst 2004;96:353-356 (Pubitemid 38351297)
16. Hortin GL. Can mass spectrometric protein profiling meet desired standards of clinical laboratory practice? Clin Chem 2005;51:3-5.
17. Diamandis EP. Oncopeptidomics: a useful approach for cancer diagnosis? Clin Chem 2007;53:1004-1006
18. Liotta LA, Petricoin EF. Putting the "bio" back into biomarkers: orienting proteomic discovery toward biology and away from the measurement platform. Clin Chem 2008;54:3-5.
19. Banks RE, Stanley AJ, Cairns DA, et al. Influences of blood sample processing on low molecular-weight proteome identified by surface-enhanced laser desorption/ionization mass spectrometry. Clin Chem 2005;51:1637-1649 (Pubitemid 41233099)
20. Diamandis EP. Peptidomics for cancer diagnosis: present and future. J Proteome Res 2006;5:2079-2082 (Pubitemid 44330798)
21. Banks RE. Preanalytical influences in clinical proteomic studies: raising awareness of fundamental issues in sample banking. Clin Chem 2008;54:6-7.
22. Baumann S, Ceglarek U, Fiedler GM, Lembcke J, Leichtle A, Thiery J. Standardized approach to proteome profiling of human serum based on magnetic bead separation and matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. Clin Chem 2005;51:973-980 (Pubitemid 40740877)
23. Findeisen P, Sismanidis D, Riedl M, Costina V, Neumaier M. Preanalytical impact of sample handling on proteome profiling experiments with matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. Clin Chem 2005;51:2409-2411 (Pubitemid 41692601)
24. Rai AJ, Vitzthum F. Effects of preanalytical variables on peptide and protein measurements in human serum and plasma: implications for clinical proteomics. Expert Rev Proteomics 2006;3:409-426 (Pubitemid 44231984)
25. Fiedler GM, Baumann S, Leichtle A, et al. Standardized peptidome profiling of human urine by magnetic bead separation and matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. Clin Chem 2007;53:421-428 (Pubitemid 46447938)
26. Bruegel M, Planert M, Baumann S, et al. Standardized peptidome profiling of human cerebrospinal fluid by magnetic bead separation and matrix-assisted laser desorption/ionization time-of- flight mass spectrometry. J Proteomics 2009;72:608-615
27. Conrad TOF, Leichtle A, Hagehülsmann A, et al. Beating the noise: new statistical methods for detecting signals in MALDI-TOF spectra below noise level. In: M.R. Berthold R.G., Fischer I., editors. Springer-Verlag Berlin Heidelberg; 2006, p. 119-128
28. Ketterlinus R, Hsieh SY, Teng SH, Lee H, Pusch W. Fishing for biomarkers: analyzing mass spectrometry data with the new ClinProTools software. Biotechniques 2005;Suppl:37-40.
29. Bruker. Clinprotools 2.0 user manual: Bruker Daltonik GmbH; 2005.
30. McLerran D, Grizzle WE, Feng Z, et al. Analytical validation of serum proteomic profiling for diagnosis of prostate cancer: sources of sample bias. Clin Chem 2008;54:44-52.
31. Diamandis EP. Mass spectrometry as a diagnostic and a cancer biomarker discovery tool: opportunities and potential limitations. Mol Cell Proteomics 2004;3:367-378 (Pubitemid 38702090)
32. Pepe MS, Etzioni R, Feng Z, et al. Phases of biomarker development for early detection of cancer. J Natl Cancer Inst 2001;93:1054-1061 (Pubitemid 32717537)
33. van der Merwe DE, Oikonomopoulou K, Marshall J, Diamandis EP. Mass spectrometry: uncovering the cancer proteome for diagnostics. Adv Cancer Res 2007;96:23-50.
34. Chen R, Pan S, Brentnall TA, Aebersold R. Proteomic profiling of pancreatic cancer for biomarker discovery. Mol Cell Proteomics 2005;4:523-533 (Pubitemid 40590569)
35. Koopmann J, Zhang Z, White N, et al. Serum diagnosis of pancreatic adenocarcinoma using surface-enhanced laser desorption and ionization mass spectrometry. Clin Cancer Res 2004;10:860-868 (Pubitemid 38198884)
36. Meuwis MA, Fillet M, Geurts P, et al. Biomarker discovery for inflammatory bowel disease, using proteomic serum profiling. Biochem Pharmacol 2007;73:1422-1433 (Pubitemid 46469959)
37. Lam YW, Mobley JA, Evans JE, Carmody JF, Ho SM. Mass profiling-directed isolation and identification of a stage-specific serologic protein biomarker of advanced prostate cancer. Proteomics 2005;5:2927-2938 (Pubitemid 41059769)
38. Maurer AM, Zhou B, Han ZC. Roles of platelet factor 4i n hematopoiesis and angiogenesis. Growth Factors 2006;24:242-252 (Pubitemid 46969817)
39. McLaren KM, Pepper DS. The immunoelectronmicroscopic localization of human platelet factor 4 in tissue mast cells. Histochem J 1983;15:795-800.
40. Bikfalvi A. Platelet factor 4: an inhibitor of angiogenesis. Semin Thromb Hemost 2004;30:379-385 (Pubitemid 39037632)
41. Soucek L, Lawlor ER, Soto D, Shchors K, Swigart LB, Evan GI. Mast cells are required for angiogenesis and macroscopic expansion of Myc-induced pancreatic islet tumors. Nat Med 2007;13:1211-1218 (Pubitemid 47530639)
42. Theoharides TC. Mast cells and pancreatic cancer. N Engl J Med 2008;358:1860-1861
43. Villanueva J, Shaffer DR, Philip J, et al. Differential exoprotease activities confer tumor-specific serum peptidome patterns. J Clin Invest 2006;116:271-284 (Pubitemid 43121812)
44. Villanueva J, Martorella AJ, Lawlor K, et al. Serum peptidome patterns that distinguish metastatic thyroid carcinoma from cancer-free controls are unbiased by gender and age. Mol Cell Proteomics 2006;5:1840-1852 (Pubitemid 44688193)
45. Van den Steen PE, Proost P, Wuyts A, Van Damme J, Opdenakker G. Neutrophil gelatinase B potentiates interleukin-8 tenfold by amino-terminal processing, whereas it degrades CTAP-III, PF-4, and GRO-α and leaves RANTES and MCP-2 intact. Blood 2000;96:2673-2681
46. Patten LC, Berger DH. Role of proteases in pancreatic carcinoma. World J Surg 2005;29:258-263 (Pubitemid 40768034)
47. Tian M, Cui YZ, Song GH, et al. Proteomic analysis identifies MMP-9, DJ-1 and A1BG as over-expressed proteins in pancreatic juice from pancreatic ductal adenocarcinoma patients. BMC Cancer 2008;8:241.